Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

40.28
+2.286.00%
Volume:805.51K
Turnover:32.03M
Market Cap:4.77B
PE:-7.65
High:40.44
Open:38.44
Low:38.12
Close:38.00
Loading ...

Cytokinetics: Promising Drug Pipeline and Strategic Vision Drive Buy Rating

TIPRANKS
·
14 Jan

Cytokinetics’ Promising Future: Aficamten Approval and Robust Pipeline Drive Growth Prospects

TIPRANKS
·
14 Jan

Cautious Hold on Cytokinetics Amid Regulatory Uncertainties and Distant Milestones

TIPRANKS
·
14 Jan

Cytokinetics CEO not looking to be bought, but would listen, STAT says

TIPRANKS
·
14 Jan

BRIEF-Cytokinetics Announces 2025 Corporate Milestones And Vision 2030

Reuters
·
13 Jan

Cytokinetics provided milestones expected in 2025

TIPRANKS
·
13 Jan

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

THOMSON REUTERS
·
13 Jan

Cytokinetics Inc - Pdufa Target Action Date for Aficamten Set for September 26, 2025

THOMSON REUTERS
·
13 Jan

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Jan

H.C. Wainwright Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
24 Dec 2024

Cytokinetics Says European Regulator Validated its Application for Cardiomyopathy Drug Candidate

MT Newswires Live
·
23 Dec 2024

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
23 Dec 2024

Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025

THOMSON REUTERS
·
23 Dec 2024

Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
23 Dec 2024

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Motley Fool
·
21 Dec 2024

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024

Sanofi to acquire rights to develop, commercialize aficamten from Corxel

TIPRANKS
·
20 Dec 2024

Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China

MT Newswires Live
·
20 Dec 2024

Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi

THOMSON REUTERS
·
20 Dec 2024

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

THOMSON REUTERS
·
20 Dec 2024